Document › Details

AMP Biosimilars AG. (4/2/15). "Press Release: AMP Biosimilars AG – Second German “Pure Play” Biosimilars Listing. Successful Trading Launch on the Munich Stock Exchange". Hamburg.

Region Region München (Munich)
  Country Germany
Organisations Organisation AMP Biosimilars AG
  Organisation 2 Formycon AG
  Group Formycon (Group)
Products Product DRUGS, BIOGEN, GENERICS (biosimilars / biogenerics)
  Product 2 investment banking
Persons Person Hentz, Marc W. (AMP Biosimilars AG 201505 CEO before AMP-Therapeutics GmbH 201210 Managing Director)
  Person 2 Lorenz, Fabian (MC Services 201504– Senior Consultant)

- Biosimilars are one of the fastest growing sectors in the pharmaceutical industry

- Listings on other exchanges and stock market segments anticipated

amp biosimilars AG (ISIN: DE00A0SMU87), a company specializing in the development of high quality biosimilars, was successfully listed on the stock exchange yesterday. The closing price on the first day of trading was 13.00 Euros. A total of 2,050,000 shares were listed for trading. This initial listing was on the over-the-counter market at the Munich Stock Exchange.

"As a highly innovative company in the fastest growing segment of the pharmaceutical industry, the listing is just our first step into capital markets," says Dr. Marc W. Hentz, Chief Executive Officer of amp biosimilars AG. “In the coming weeks we will be using management roadshows and investor conferences to outline our outstanding prospects while establishing our company’s reputation for transparency and candor in the capital marketplace.”

Biosimilars are imitations of existing bio-pharmaceuticals and constitute one of the fastest growing segments of the pharmaceutical industry. According to market studies, sales of biosimilars are expected to grow in the next 10 years to accumulated 100 billion US dollars from the current three billion US dollars. Biosimilars are more affordable than original products and provide access to new therapies for a far greater number of patients.

amp biosimilars is headquartered in Hamburg and focuses on the development of high quality biosimilars. The company employs its own unique approach, allowing it to make biosimilars faster, more efficiently and more affordably than the competition.

Owing to excellent market potential, companies in the segment are currently very popular among investors. Along with Munich-based Formycon AG (ISIN: DE000A1EWVY8), amp biosimilars is only the second German "pure play" company in the biosimilars segment currently on the market. The first pure biosimilars companies in the US, like Coherus Biosciences Inc. (ISIN: US19249H1032), have also celebrated their own successful initial public listings.

Following this successful listing on the Munich Stock Exchange, further listings will follow over the next few months. Launches in multiple market segments are also planned.

About amp biosimilars AG:

amp biosimilars AG develops high quality biosimilars to meet the growing demand in global therapeutic markets and is one of the most innovative and dynamic biosimilars companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. A research platform that employs state-of-the-art analytics, process technology and clinical expertise combined with regulatory know-how are what make amp biosimilars AG one of the leading companies in biosimilars development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to some of the fastest growing markets in the world. Through its unique approach, amp biosimilars can both challenge the dominance of global leaders in the pharmaceutical industry while also maintaining its central role in one of the fastest growing markets in the life sciences segment over the coming years. For more information, please go to


MC Services AG
Fabian Lorenz
T +49 211 529252-28

Record changed: 2017-04-02


Picture [LSUS] – The Business Web Portal 650x112px

More documents for AMP Biosimilars AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] – Putting Information into Context 600x60px

» top